Marshall Wace, LLP Nuvectis Pharma, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 124,571 shares of NVCT stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
124,571
Previous 42,814
190.96%
Holding current value
$1.29 Million
Previous $269,000
151.3%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NVCT
# of Institutions
33Shares Held
2.23MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$5.81 Million5.37% of portfolio
-
Baldwin Brothers LLC358KShares$3.7 Million0.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA325KShares$3.36 Million0.0% of portfolio
-
Iridian Asset Management LLC254KShares$2.62 Million0.82% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$861,6450.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $151M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...